drugset / Trial / NCT00281736

Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer

NCT00281736 ↗

Phase 2 Completed 60 enrolled Roswell Park Cancer Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that is absorbed by tumor cells. The drug becomes active when it is exposed to light, and kills tumor cells. HPPH may be effective in killing precancerous cells and tumor cells. PURPOSE: This randomized phase II trial is studying how well photodynamic therapy with HPPH works in treating patients with precancerous esophageal conditions or stage 0 or stage I esophageal cancer.

Timeline

Start
2004-02
Primary completion
2007-07
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown — Intravenous